GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

Are you a print subscriber? Activate your account. By Tim Nudd - 1 hour 14 min ago By Adrianne Pasquarelli - 5 hours 42 min ago By Erika Wheless - 5 hours 42 min ago By Brian Bonilla - 5 hours 42 ...

Grant Thornton Ireland’s 45 equity partners are set to receive €6.5 million each under a cash-and-shares-based merger of its non ... US pharmaceuticals giant Pfizer, which employs 5,000 ...

Consumer Health restructuring The merger of GlaxoSmithKline and Pfizer is dragging on sales—up 1 percent in 2019—as the businesses streamline. This compares with a Glaxo consumer ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Also Read: GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations The vaccine is currently approved for active immunization to prevent RSV-LRTD in ...